{"id":"s-217622","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL5183847","moleculeType":"Small molecule","molecularWeight":"531.89"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"S-217622 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and increasing glucose excretion in the urine. This leads to a decrease in blood glucose levels. S-217622 is being investigated for its potential to improve glycemic control in patients with type 2 diabetes.","oneSentence":"S-217622 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:00.071Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05605093","phase":"PHASE3","title":"Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2022-12-23","conditions":"COVID-19","enrollment":602},{"nctId":"NCT05305547","phase":"PHASE3","title":"A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19","status":"COMPLETED","sponsor":"Shionogi","startDate":"2022-08-03","conditions":"SARS-CoV-2 Infection","enrollment":2093},{"nctId":"NCT05897541","phase":"PHASE3","title":"Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"Shionogi","startDate":"2023-06-09","conditions":"SARS-CoV-2 Infection","enrollment":2387},{"nctId":"NCT06775730","phase":"PHASE1","title":"A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants","status":"COMPLETED","sponsor":"Shionogi","startDate":"2024-12-30","conditions":"Healthy Adult Female Participants","enrollment":24},{"nctId":"NCT06161688","phase":"PHASE2","title":"Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID","status":"ACTIVE_NOT_RECRUITING","sponsor":"Timothy Henrich","startDate":"2024-04-09","conditions":"Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19","enrollment":40},{"nctId":"NCT05409911","phase":"PHASE1","title":"A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants","status":"COMPLETED","sponsor":"Shionogi","startDate":"2022-09-13","conditions":"Hepatic Impairment","enrollment":25},{"nctId":"NCT05363215","phase":"PHASE1","title":"A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants","status":"COMPLETED","sponsor":"Shionogi","startDate":"2022-08-10","conditions":"Renal Impairment","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"S-217622","genericName":"S-217622","companyName":"Shionogi","companyId":"shionogi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"S-217622 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}